Hims vs Ro vs Henry vs MEDVi: the telehealth GLP-1 matrix in April 2026
Four telehealth providers, four pricing structures, four clinical approaches. Here's how they compare on what actually matters — product, cost, intake, and ongoing care.
The end of compounded GLP-1s restructured the telehealth GLP-1 market. Providers that had built businesses on cheap compounded semaglutide ($150–$250/month) had to pivot to branded Wegovy, Zepbound, and the manufacturer direct-to-patient programs (NovoCare, LillyDirect). A year into that transition, the four largest telehealth GLP-1 providers have differentiated on pricing, clinical depth, and target patient.
This article contains affiliate links. If you sign up through our links, we may earn a commission at no additional cost to you. We only partner with providers we'd cover regardless. See our editorial policy.
Hims & Hers
The largest telehealth GLP-1 provider by volume. Hims prescribes branded Wegovy and Zepbound with medical consultation, handles prior authorization submission for commercially insured patients, and coordinates with the manufacturer direct-to-patient programs for uninsured patients. Consultation fee: typically $0–$100 initial, $0–$40/month ongoing. Drug cost: passed through (insurance covered + copay, or NovoCare/LillyDirect rate). Best fit: mass-market patients who want a straightforward telehealth experience.
Ro
Similar product to Hims at a slightly smaller scale. Ro was early to the compounded GLP-1 boom and has rebuilt around branded products. Ro's clinical intake is marginally more rigorous in our review of their workflow — more detailed medical-history questions, more prior-authorization follow-through. Consultation fee: comparable to Hims. Best fit: patients with complex medical history who want the telehealth convenience but more clinical depth.
Henry Meds
Henry Meds operates at the premium end. Higher consultation fees, more hands-on clinical management, longer monthly check-ins. For patients who value the medical-care layer as much as the drug access, Henry Meds differentiates on clinician time. Best fit: patients who want telehealth convenience but expect the consultation to feel like meaningful medical care, not a prescription conveyor belt.
MEDVi
MEDVi has taken a different path — they've built out ancillary services (bloodwork ordering, body composition tracking, continuing-care check-ins) at a higher price point. Their target patient is someone integrating GLP-1 into a broader metabolic-health program, not just seeking drug access. Best fit: patients who want the drug + the wraparound clinical program.
What to ask before picking
Four questions worth getting answers to before signing up for any of them:
**Is this branded Wegovy or Zepbound, or is it something else?** Any legitimate 2026 telehealth GLP-1 provider is prescribing FDA-approved branded products. If they're offering "research peptide" anything, walk away.
**What happens if my insurance denies prior auth?** Some providers aggressively appeal; others pass the denial to you and move on. This materially affects real-world cost.
**Is there a dedicated clinician, or a shuffle?** Continuity matters for dose escalation, side-effect management, and labs.
**What's the ongoing cost structure — subscription, per-consultation, or bundled with drug?** Surprises here cost people meaningful money across a year of treatment.
Sources